SSA
DRUG

Schonfeld Strategic Advisors’s Bright Minds Biosciences DRUG Stock Holding History

Schonfeld Strategic Advisors’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$966K Sell
13,244
-16,967
-56% -$1.37M 0.01% 1115
2025
Q4 		$2.36M Sell
30,211
-36,395
-55% -$2.43M 0.01% 816
2025
Q3 		$4.04M Sell
66,606
-2,398
-3% -$93.1K 0.02% 681
2025
Q2 		$1.8M Sell
69,004
-6,597
-9% -$198K 0.01% 1040
2025
Q1 		$2.72M Buy
75,601
+5,789
+8% +$212K 0.02% 807
2024
Q4 		$2.46M Buy
+69,812
New +$2.46M 0.01% 751

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Schonfeld Strategic Advisors's DRUG Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Bright Minds Biosciences (DRUG) stake by 56% in Q1 2026, selling an estimated $1.37M and leaving 13,244 shares worth $966K. The position accounts for 0.01% of the portfolio, ranked #1115.

Schonfeld Strategic Advisors first reported a position in DRUG in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.04M in Q3 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Schonfeld Strategic Advisors held 13,244 shares of Bright Minds Biosciences worth $966K as of Q1 2026.
  • Schonfeld Strategic Advisors sold 16,967 Bright Minds Biosciences shares in Q1 2026, an estimated $1.37M.
  • Bright Minds Biosciences made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1115 holding.
  • Schonfeld Strategic Advisors first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Schonfeld Strategic Advisors's Bright Minds Biosciences position peaked at $4.04M in Q3 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.